PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis

NYSE:PBH • US74112D1019

68.53 USD
-0.77 (-1.11%)
At close: Mar 2, 2026
68.53 USD
0 (0%)
After Hours: 3/2/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

PBH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. PBH has an excellent profitability rating, but there are some minor concerns on its financial health. PBH has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PBH was profitable.
  • PBH had a positive operating cash flow in the past year.
  • Of the past 5 years PBH 4 years were profitable.
  • PBH had a positive operating cash flow in each of the past 5 years.
PBH Yearly Net Income VS EBIT VS OCF VS FCFPBH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

1.2 Ratios

  • PBH has a better Return On Assets (5.34%) than 87.05% of its industry peers.
  • PBH has a Return On Equity of 10.19%. This is amongst the best in the industry. PBH outperforms 85.49% of its industry peers.
  • With an excellent Return On Invested Capital value of 7.55%, PBH belongs to the best of the industry, outperforming 86.53% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.91%.
Industry RankSector Rank
ROA 5.34%
ROE 10.19%
ROIC 7.55%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
PBH Yearly ROA, ROE, ROICPBH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20

1.3 Margins

  • PBH has a better Profit Margin (16.90%) than 89.12% of its industry peers.
  • PBH's Profit Margin has improved in the last couple of years.
  • The Operating Margin of PBH (30.34%) is better than 94.30% of its industry peers.
  • PBH's Operating Margin has been stable in the last couple of years.
  • With a decent Gross Margin value of 56.12%, PBH is doing good in the industry, outperforming 68.39% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
Industry RankSector Rank
OM 30.34%
PM (TTM) 16.9%
GM 56.12%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
PBH Yearly Profit, Operating, Gross MarginsPBH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, PBH has less shares outstanding
  • PBH has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PBH has been reduced compared to a year ago.
PBH Yearly Shares OutstandingPBH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PBH Yearly Total Debt VS Total AssetsPBH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • PBH has an Altman-Z score of 2.58. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PBH's Altman-Z score of 2.58 is fine compared to the rest of the industry. PBH outperforms 67.36% of its industry peers.
  • PBH has a debt to FCF ratio of 3.95. This is a good value and a sign of high solvency as PBH would need 3.95 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.95, PBH belongs to the top of the industry, outperforming 88.08% of the companies in the same industry.
  • PBH has a Debt/Equity ratio of 0.58. This is a neutral value indicating PBH is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.58, PBH is not doing good in the industry: 64.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 3.95
Altman-Z 2.58
ROIC/WACC0.87
WACC8.64%
PBH Yearly LT Debt VS Equity VS FCFPBH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.3 Liquidity

  • PBH has a Current Ratio of 3.11. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
  • PBH has a Current ratio (3.11) which is in line with its industry peers.
  • A Quick Ratio of 1.93 indicates that PBH should not have too much problems paying its short term obligations.
  • The Quick ratio of PBH (1.93) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 1.93
PBH Yearly Current Assets VS Current LiabilitesPBH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PBH shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.92%.
  • PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
  • PBH shows a decrease in Revenue. In the last year, the revenue decreased by -1.31%.
  • The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.28% on average over the next years.
  • The Revenue is expected to grow by 0.71% on average over the next years.
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PBH Yearly Revenue VS EstimatesPBH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
PBH Yearly EPS VS EstimatesPBH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.30, the valuation of PBH can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 87.56% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.13, PBH is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 14.07, PBH is valued correctly.
  • Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 85.49% of the companies in the same industry.
  • PBH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.3
Fwd PE 14.07
PBH Price Earnings VS Forward Price EarningsPBH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 86.01% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PBH is valued cheaply inside the industry as 89.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.14
EV/EBITDA 11.6
PBH Per share dataPBH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
  • PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)9.82
PEG (5Y)1.72
EPS Next 2Y3.7%
EPS Next 3Y3.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PBH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRESTIGE CONSUMER HEALTHCARE

NYSE:PBH (3/2/2026, 8:04:00 PM)

After market: 68.53 0 (0%)

68.53

-0.77 (-1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners108.83%
Inst Owner Change0.3%
Ins Owners1.31%
Ins Owner Change-0.48%
Market Cap3.24B
Revenue(TTM)1.10B
Net Income(TTM)186.50M
Analysts84
Price Target78.95 (15.21%)
Short Float %4.68%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.91%
Min EPS beat(2)-1.36%
Max EPS beat(2)9.18%
EPS beat(4)2
Avg EPS beat(4)0.63%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)4
Avg EPS beat(8)-0.63%
EPS beat(12)6
Avg EPS beat(12)-46.73%
EPS beat(16)10
Avg EPS beat(16)-34.55%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)5.55%
Revenue beat(4)2
Avg Revenue beat(4)0.29%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)-0.13%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-1.13%
EPS NY rev (1m)-0.08%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)-2.24%
Revenue NQ rev (3m)-2.61%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)-0.09%
Valuation
Industry RankSector Rank
PE 15.3
Fwd PE 14.07
P/S 2.94
P/FCF 12.14
P/OCF 11.72
P/B 1.77
P/tB N/A
EV/EBITDA 11.6
EPS(TTM)4.48
EY6.54%
EPS(NY)4.87
Fwd EY7.11%
FCF(TTM)5.65
FCFY8.24%
OCF(TTM)5.85
OCFY8.53%
SpS23.32
BVpS38.66
TBVpS-22.26
PEG (NY)9.82
PEG (5Y)1.72
Graham Number62.43
Profitability
Industry RankSector Rank
ROA 5.34%
ROE 10.19%
ROCE 9.98%
ROIC 7.55%
ROICexc 7.69%
ROICexgc 61.8%
OM 30.34%
PM (TTM) 16.9%
GM 56.12%
FCFM 24.21%
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 3.95
Debt/EBITDA 2.88
Cap/Depr 31.31%
Cap/Sales 0.86%
Interest Coverage 7.66
Cash Conversion 75.79%
Profit Quality 143.26%
Current Ratio 3.11
Quick Ratio 1.93
Altman-Z 2.58
F-Score5
WACC8.64%
ROIC/WACC0.87
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.92%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-6.56%
EPS Next Y1.56%
EPS Next 2Y3.7%
EPS Next 3Y3.57%
EPS Next 5Y4.28%
Revenue 1Y (TTM)-1.31%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-2.37%
Revenue Next Year-2.45%
Revenue Next 2Y-0.18%
Revenue Next 3Y0.52%
Revenue Next 5Y0.71%
EBIT growth 1Y1.3%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year5.29%
EBIT Next 3Y3.49%
EBIT Next 5Y2.82%
FCF growth 1Y15.15%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y14.78%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PBH.


Can you provide the valuation status for PRESTIGE CONSUMER HEALTHCARE?

ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.


What is the profitability of PBH stock?

PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.


What is the expected EPS growth for PRESTIGE CONSUMER HEALTHCARE (PBH) stock?

The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 1.56% in the next year.